期刊
JOURNAL OF NUTRITION HEALTH & AGING
卷 15, 期 8, 页码 725-730出版社
SPRINGER FRANCE
DOI: 10.1007/s12603-011-0058-9
关键词
Sarcopenia; clinical trials; study design; skeletal muscle; aging; muscle strength; older persons
资金
- University of Florida Institute on Aging
- Claude D. Pepper older Americans Independence Center (NIH) [1P30AG028740]
- National Institutes of Health - National Institute on Aging (NIA) [1R01AG02655601A2]
Despite the existing limitations and controversies regarding the definition of sarcopenia and its clinical consequences, the current scientific evidence strongly suggests that muscle decline is a primary determinant of the disabling process (and likely of other major health-related events). In fact, the muscle loss (in terms of mass as well as strength) occurring with aging has been growingly associated with mobility impairment and disability in older persons. Unfortunately, current evidence is mainly from observational studies. Times are mature to begin testing interventions aimed at modifying the sarcopenia process through the design and development of specific clinical trials. Considering the emergence of many promising interventions towards this age-related condition (e.g., physical exercise [in particular, resistance training], testosterone, antioxidant supplementations), the need for Phase II trial designs is high. In the present report, we discuss which are the major issues related to the design of Phase II clinical trials on sarcopenia with particular focus on the participant's characteristics to be considered as possible inclusion and exclusion criteria.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据